Nexeon Medsystems

About Nexeon Medsystems

Nexeon MedSystems, Inc., established in 2005, operates as a medical device company with a focus on developing and commercializing neurostimulation technology. The company was founded by Will Rosellini, who brought his background in neuroscience and business to steer the company's direction. Nexeon's core business revolves around creating active, implantable medical devices designed to treat various neurological disorders.

The company's primary product is a deep brain stimulation (DBS) system, which functions as a neurostimulator for managing symptoms associated with Parkinson's disease. This system is designed to be a programmable, implantable pulse generator that delivers electrical stimulation to targeted areas of the brain. A significant feature of their technology is the ability to record brain signals (local field potentials) at the same time as providing stimulation, which offers the potential for data-driven, patient-specific therapy adjustments. This dual function allows for a more closed-loop, responsive approach to neurostimulation, moving beyond traditional open-loop systems.

Nexeon MedSystems operates within the bioelectronics and medical device markets, targeting patients and healthcare providers in the neurology sector. The company's business model appears to be centered on the manufacturing and sale of these advanced medical devices. In a strategic move to vertically integrate its operations, Nexeon acquired Nexeon MedSystems Belgium (NMSB), formerly a subsidiary of Boston Scientific. This acquisition provided Nexeon with an operational manufacturing facility and an experienced team, enhancing its capabilities in device production and development.

The company has also engaged in strategic partnerships, such as a collaboration with the University of Texas at Dallas, to further research and develop its neurostimulation platform. Nexeon was a publicly traded company under the ticker NXNN, providing it with access to capital markets for funding its research, development, and commercialization efforts.